147 related articles for article (PubMed ID: 17428174)
1. Molecular predictors of chemotherapy response in non-small-cell lung cancer.
Gray J; Simon G; Bepler G
Expert Rev Anticancer Ther; 2007 Apr; 7(4):545-9. PubMed ID: 17428174
[TBL] [Abstract][Full Text] [Related]
2. Molecular predictors of response to chemotherapy in non-small cell lung cancer.
Andrews J; Yeh P; Pao W; Horn L
Cancer J; 2011; 17(2):104-13. PubMed ID: 21427554
[TBL] [Abstract][Full Text] [Related]
3. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
4. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
Sève P; Reiman T; Dumontet C
Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
Simon G; Sharma A; Li X; Hazelton T; Walsh F; Williams C; Chiappori A; Haura E; Tanvetyanon T; Antonia S; Cantor A; Bepler G
J Clin Oncol; 2007 Jul; 25(19):2741-6. PubMed ID: 17602079
[TBL] [Abstract][Full Text] [Related]
6. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
7. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
[TBL] [Abstract][Full Text] [Related]
8. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
[TBL] [Abstract][Full Text] [Related]
9. Evolution of therapy decision-making process for advanced non-small cell lung cancer.
Gebbia V; Mancuso G; Lombardi L; Maiello E
Oncology; 2009; 77 Suppl 1():97-102. PubMed ID: 20130437
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
[TBL] [Abstract][Full Text] [Related]
11. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
Pérez-Soler R
Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
[TBL] [Abstract][Full Text] [Related]
12. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
Felip E; Rosell R
Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
[TBL] [Abstract][Full Text] [Related]
13. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
Kandioler D; Stamatis G; Eberhardt W; Kappel S; Zöchbauer-Müller S; Kührer I; Mittlböck M; Zwrtek R; Aigner C; Bichler C; Tichy V; Hudec M; Bachleitner T; End A; Müller MR; Roth E; Klepetko W
J Thorac Cardiovasc Surg; 2008 May; 135(5):1036-41. PubMed ID: 18455581
[TBL] [Abstract][Full Text] [Related]
14. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data.
Kim B; Lee HJ; Choi HY; Shin Y; Nam S; Seo G; Son DS; Jo J; Kim J; Lee J; Kim J; Kim K; Lee S
Cancer Res; 2007 Aug; 67(15):7431-8. PubMed ID: 17671213
[TBL] [Abstract][Full Text] [Related]
15. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.
Li R; An SJ; Chen ZH; Zhang GC; Zhu JQ; Nie Q; Xie Z; Guo AL; Mok TS; Wu YL
Hum Pathol; 2008 Dec; 39(12):1792-801. PubMed ID: 18715616
[TBL] [Abstract][Full Text] [Related]
16. New targets for non-small-cell lung cancer therapy.
Alvarez M; Roman E; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics in non-small-cell lung cancer chemotherapy.
Danesi R; Pasqualetti G; Giovannetti E; Crea F; Altavilla G; Del Tacca M; Rosell R
Adv Drug Deliv Rev; 2009 May; 61(5):408-17. PubMed ID: 19292993
[TBL] [Abstract][Full Text] [Related]
18. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
19. Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective.
Dziadziuszko R; Hirsch FR
Clin Lung Cancer; 2008 Mar; 9(2):78-84. PubMed ID: 18501093
[TBL] [Abstract][Full Text] [Related]
20. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
